PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Небольшая подборка полезной литературы

Опубликовано 6 марта, 201930 июня, 2019 frozencat

Data And Safety Monitoring Committees In Clinical Trials

Epidemiology and Biostatistics An Introduction to Clinical Research

Statistical Methods for Survival Trial Design: With Applications to Cancer Clinical Trials Using R

Clinical trial data analysis with R and SAS

Clinical Trials Design in Operative and Non Operative Invasive Procedures

Analyzing Longitudinal Clinical Trial Data: A Practical Guide

Bioequivalence and Statistics in Clinical Pharmacology, Second Edition

Design and Analysis of Bioavailability and Bioequivalence Studies

Biomaterials in Clinical Practice : Advances in Clinical Research and Medical Devices

Fundamental Statistical Inference A Computational Approach

Statistics and Simulation

Medical biostatistics

Biostatistics

Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development

Biosimilar Clinical Development: Scientific Considerations and New Methodologies

Рубрики: Блог, Общее

Навигация по записям

Предыдущая запись: Расчет доверительных интервалов для 2X2 биоэквивалентности: Julia concept code
Следующая запись: Протокол и отчет клинического исследования биоэквивалентности: шаблон

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

IMG-20170802-WA0012
IMG-20170802-WA0007
20180202 161927
IMG-20170806-WA0007
20180131 164914
20180815 154749
  • Generic Drug User Fee Amendments
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-30 By FDA
  • October - December 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • eCTD Submission Standards for eCTD v3.2.2 and Regional M1
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • eCTD Submission Standards for eCTD v4.0 and Regional M1
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • Internet Pharmacy Warning Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 36, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Date of authorisation: 20/06/2019, Revision: 11, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Green Lumber Holding, LLC Issues Consumer Alert on Counterfeit Products Following FDA Findings
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-08-29 By FDA
  • Human medicines European public assessment report (EPAR): Nubeqa, darolutamide, Date of authorisation: 27/03/2020, Revision: 10, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Jeraygo, aprocitentan, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
  • Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-08-29
Предыдущие записи
Тема: Scaffold от Danny Cooper.